Overview
Diroximel fumarate and its active metabolite, monomethyl fumarate (MMF), have been shown to activate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, which is involved in cellular response to oxidative stress. The mechanism by which diroximel fumarate exerts a therapeutic effect in multiple sclerosis is from its anti-inflammatory and cytoprotective properties via activation of the Nrf2 pathway. MMF has also been identified as a nicotinic acid receptor agonist in vitro.

Coverage Guidelines
Authorization may be granted for members who are currently receiving treatment with Vumerity when the product is obtained as samples or via manufacturer’s patient assistance programs.

OR
Authorization may be granted for members when all the following criteria are met, and documentation is provided:
1. The member is ≥ 18 years of age
2. The member has a diagnosis of multiple sclerosis (MS)
3. The member has a relapsing form of MS including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
4. The provider specialty is neurology or medication is being used in consultation with a neurologist

Continuation of Therapy
Reauthorization requires physician documentation of improvement of member’s condition.

Limitations
1. Initial approvals will be for 6 months.
2. Reauthorizations will be for 24 months
3. The following quantity limits apply:

| Vumerity 231mg | 120 capsules per 30 days |

References

Review History
07/22/2020 – Reviewed and Created May P&T Mtg. Effective 9/1/2020

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.